BioArctic AB (publ) (BIOA-B)
Stockholm Exchange · Sweden · prices in SEK · close of 19 Oct 2026
Key indicators
| Last close | SEK 289.00 |
|---|---|
| 52-week range | 255.49 – 362.25 |
| Return, 1 month / 3 months | −10.0% / −6.2% |
| Return, 1 year / 3 years | −4.3% / +7.7% |
| Trend | Below its 200-day average |
| RSI (14) | 37 |
| Volatility (1 year) | 42.2% |
| Worst drawdown (1 year) | -22.5% |
| Average daily value traded | 46.94M SEK |
| Dividend yield | 0.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
BioArctic is a Swedish biopharmaceutical company that researches and develops treatments for neurodegenerative diseases. Its work centres on antibodies and other therapies aimed at conditions such as Alzheimer's disease and Parkinson's disease. The company carries out its own drug discovery and development and works with larger pharmaceutical partners on later-stage programmes. BioArctic is based in Stockholm, Sweden, and its customers and collaborators are mainly pharmaceutical companies and research organisations involved in neuroscience.
The shares are listed on the Stockholm Exchange in Sweden under the code BIOA-B, and the price on this page is in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
BioArctic AB (publ) (BIOA-B) trades on the Stockholm Exchange in Sweden. It last closed at SEK 289.00 on 19 October 2026.
Its price-based Market X-Ray is 59 out of 100 (a fair price profile), ranking 338 of 911 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 4.3% and over the last three months it fell 6.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 55 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -8.8% | ||
| From 52-week high | -20.2% | ||
| Momentum | 53 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -6.2% | ||
| 6-month return | -8.5% | ||
| 12-month return, skipping the last month | 6.3% | ||
| Stability (higher is calmer) | 72 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 42.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.5% | ||
| Liquidity | 91 · Strong | Trades actively. | |
| Average daily value traded | 46.94M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 5 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.7% | ||
| Years with dividends | 1 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −3.1% |
|---|---|
| 1 month | −10.0% |
| 3 months | −6.2% |
| 6 months | −8.5% |
| 1 year | −4.3% |
| 3 years | +7.7% |
| 5 years | – |
Signals
| 50-day / 200-day average | 317.14 / 316.92 |
|---|---|
| Golden / death cross (60 days) | Golden, 45 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 8.97 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 May 2026 | SEK 2.0000 |
| 10 May 2019 | SEK 1.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.